No photo of Jeffrey A Allen
Contact Expert

View Scopus Profile

Jeffrey A Allen

20002019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

  • 1 Similar Profiles
Chronic Inflammatory Demyelinating Polyradiculoneuropathy Medicine & Life Sciences
Peripheral Nervous System Diseases Medicine & Life Sciences
Eosinophilia-Myalgia Syndrome Medicine & Life Sciences
Polyneuropathies Medicine & Life Sciences
Intravenous Immunoglobulins Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Epidemic Pleurodynia Medicine & Life Sciences
Immunoglobulins Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2014 2019

A Phase III, Double-Blind, Randomized, Placebo-Controlle

Allen, J. A.

ViroMed Co., Ltd.

3/1/16 → 8/31/19

Project: Research project

Diabetic Neuropathies
Peripheral Nervous System Diseases
Multicenter Studies
Placebos
Safety

Intravenous Immunoglobulin (IVIg) Treatment-Related

Allen, J. A.

CSL BEHRING GMBH

6/1/14 → 8/31/19

Project: Research project

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intravenous Immunoglobulins
Hand Strength
Therapeutics

Randomized, multicenter, double-blind, placebo-controlle

Allen, J. A. & Walk, D.

CSL BEHRING GMBH

1/1/14 → 4/30/18

Project: Research project

Immunoglobulins
Placebos
Safety
Therapeutics
Hizentra

Research Output 2000 2019

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies

on Behalf of the PRIMA Trial Investigators and the PATH Study Group, Mar 1 2019, In : Journal of the Peripheral Nervous System. 24, 1, p. 48-55 8 p.

Research output: Contribution to journal › Article

Open Access
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Polyneuropathies
Intravenous Immunoglobulins
Safety
Drug-Related Side Effects and Adverse Reactions

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study

on behalf of the PATH study group, Mar 1 2019, In : Journal of the Peripheral Nervous System. 24, 1, p. 72-79 8 p.

Research output: Contribution to journal › Article

Open Access
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Polyneuropathies
Intravenous Immunoglobulins
Random Allocation
Therapeutics
1 Citation (Scopus)

Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis

Breiner, A., Bourque, P. R. & Allen, J. A., Jan 1 2019, In : Muscle and Nerve.

Research output: Contribution to journal › Article

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Cerebrospinal Fluid Proteins
Reference Values
Diagnostic Errors
Cohort Studies
2 Citations (Scopus)

231st ENMC International Workshop:: International Standard for CIDP Registry and Biobank, Naarden, The Netherlands, 12–14 May 2017

participants of the 231st ENMC workshop, Feb 1 2018, In : Neuromuscular Disorders. 28, 2, p. 178-184 7 p.

Research output: Contribution to journal › Article

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Netherlands
Registries
Education
3 Citations (Scopus)

Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy

Allen, J. A., Gorson, K. C. & Gelinas, D., Mar 1 2018, In : Brain and Behavior. 8, 3, e00932.

Research output: Contribution to journal › Article

Open Access
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intravenous Immunoglobulins
Peripheral Nerves
Guidelines
Guideline Adherence